MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Exelixis Company Profile (NASDAQ:EXEL)

Consensus Ratings for Exelixis (NASDAQ:EXEL) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $8.00 (4.03% upside)

Analysts' Ratings History for Exelixis (NASDAQ:EXEL)
Show:
DateFirmActionRatingPrice TargetActions
6/21/2016Leerink SwannReiterated RatingOutperform$8.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/26/2016Stifel NicolausBoost Price TargetBuy$7.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2016William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015Piper JaffrayReiterated RatingHold$2.50 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Exelixis (NASDAQ:EXEL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/4/2016Q116($0.25)($0.27)$9.11 million$15.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.22)($0.19)$8.16 million$9.94 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.20)($0.22)$9.08 million$9.85 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.21)($0.22)$8.69 million$8.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($0.24)($0.18)$8.08 million$9.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q414($0.31)($0.30)$7.50 million$7.35 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.37)($0.32)$6.77 million$6.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214($0.39)($0.38)$5.66 million$6.56 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114($0.37)($0.39)$6.11 million$4.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2014Q413($0.38)($0.38)$5.71 million$4.34 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2013Q313($0.37)($0.36)$5.55 million$5.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013($0.30)($0.34)$6.55 million$11.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.29)($0.24)$5.33 million$9.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/21/2013Q4 2012($0.24)($0.28)$9.46 million$7.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.30)($0.20)$9.22 million$13.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.27)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012($0.19)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011$0.57$0.60ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011($0.17)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2011($0.19)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/22/2011($0.21)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Exelixis (NASDAQ:EXEL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.27)($0.24)($0.26)
Q2 20162($0.29)($0.29)($0.29)
Q3 20162($0.28)($0.28)($0.28)
Q4 20162($0.25)($0.22)($0.24)
Q1 20171($0.22)($0.22)($0.22)
Q2 20171($0.19)($0.19)($0.19)
Q3 20171($0.16)($0.16)($0.16)
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)
Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Exelixis (NASDAQ:EXEL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/11/2016Lance WillseyDirectorBuy60,000$4.97$298,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2016Lance WillseyDirectorBuy40,000$4.97$198,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Lance WillseyDirectorBuy100,000$4.89$489,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2015Peter LambEVPSell51,549$5.80$298,984.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2015Peter LambEVPSell600$5.80$3,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/12/2015Peter LambEVPSell300,276$5.84$1,753,611.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Vincent T MarchesiDirectorBuy20,000$1.71$34,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2013Lance WillseyDirectorBuy10,000$5.15$51,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/20/2012Vincent T MarchesiDirectorBuy4,000$4.68$18,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2012Vincent T MarchesiDirectorBuy6,000$4.72$28,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2012Gisela SchwabEVPBuy25,000$4.39$109,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Exelixis (NASDAQ:EXEL)
DateHeadline
06/24/16 04:00 PMHC Stocks in Top Row: Cellectar Biosciences Inc (NASDAQ:CLRB), Exelixis, Inc. (NASDAQ:EXEL) - share market updates (press release)
06/24/16 04:00 PMExelixis Inc. (EXEL) Hits New 52-week High During June 22 Session - Equities.com
06/24/16 04:00 PMAnalysts Review of Stocks: MannKind Corporation (NASDAQ:MNKD) , Exelixis, Inc. (NASDAQ:EXEL) - Street Updates
06/23/16 02:56 PMExelixis, Inc. (NASDAQ:EXEL) Earnings Glance and Target Price Review - Engelwood Daily
06/23/16 05:10 AMAnalysis under consideration: Exelixis, Inc. (NASDAQ:EXEL) - News Oracle
06/23/16 05:10 AMExelixis Inc (NASDAQ:EXEL) price target increased to $10 as announced today by Leerink Swann - Breaking Finance News
06/23/16 05:10 AMExelixis Inc. (EXEL) Hits New 52-week High During June 21 Session - Equities.com
06/22/16 04:03 PMExelixis Inc (NASDAQ:EXEL) price target increased to $10 as announced today by Leerink Swann
06/22/16 08:38 AMHC Stocks Reports Analysis: Express Scripts Holding Company (NASDAQ:ESRX), Exelixis, Inc. (NASDAQ:EXEL) - share market updates (press release)
06/22/16 08:38 AMAnalysts Observing Trading Stocks: Merck & Company, Inc. (NYSE:MRK) , Exelixis, Inc. (NASDAQ:EXEL) - Street Updates
06/22/16 08:38 AMTake a look at Analysts Tips: Exelixis, Inc. (NASDAQ:EXEL) , Mast Therapeutics, Inc. (NYSEMKT:MSTX) - Street Updates
06/22/16 08:38 AMLeerink Pounds the Table On Exelixis, Inc. (EXEL) - Smarter Analyst
06/21/16 08:34 AMMGT Capital Investments (NYSEMKT:MGT) & Exelixis, Inc. (NASDAQ:EXEL) Stocks in the News - Wall Street 24
06/18/16 08:27 AMExelixis, Inc. Upside Stock Momentum at Extreme Strength - CML News
06/17/16 03:45 PMAnalyst's Valuable Buzzers: Exelixis, Inc. (NASDAQ:EXEL) , Vascular Biogenics Ltd. (NASDAQ:VBLT) - Street Updates
06/16/16 08:18 AMRecently Issued Stock Ratings For Exelixis, Inc. (NASDAQ:EXEL) - Fiscal Standard
06/16/16 08:18 AMHC Stocks Alerts: Exelixis, Inc. (NASDAQ:EXEL), Celgene Corporation (NASDAQ:CELG) - share market updates (press release)
06/16/16 08:18 AMAnalyst's Checklist Stocks: EXACT Sciences Corporation (NASDAQ:EXAS) , Exelixis, Inc. (NASDAQ:EXEL) - Street Updates
06/15/16 04:00 PMRatings Analysis of: Exelixis, Inc. (NASDAQ:EXEL) - News Oracle
06/15/16 04:00 PMStocks Analysts Ranking Summary: Exelixis, Inc. (NASDAQ:EXEL) , Ionis Pharmaceuticals Inc (NASDAQ:IONS) - Street Updates
06/14/16 03:50 PMWorth Watching Active Stock's News Update: Exelixis, Inc. (NASDAQ:EXEL), Boeing Co (NYSE:BA) - NYSE Journal (press release)
06/14/16 03:50 PMStocks inside Analysts Limelight: Exelixis, Inc. (NASDAQ:EXEL) , Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Street Updates
06/13/16 06:54 AMChesapeake Energy Corporation (NYSE:CHK ) & Exelixis, Inc. (NASDAQ:EXEL) News Review - Wall Street 24
06/11/16 03:58 PMExelixis Inc. (EXEL) is Trading Higher on Unusual Volume for June 09 - Equities.com
06/11/16 06:47 AMExelixis Inc. (EXEL) Hits New 52-week High During June 09 Session - Equities.com
06/10/16 04:02 PMAnalysts Observing Stocks: Exelixis, Inc. (NASDAQ:EXEL) , Celgene Corporation (NASDAQ:CELG) - Street Updates
06/09/16 07:15 AMNotable Moving HC Stocks: Exelixis, Inc. (NASDAQ:EXEL), Medtronic PLC (NYSE:MDT) - share market updates (press release)
06/09/16 07:15 AMNotable Analysts Recommendation to Monitor: Exelixis, Inc. (NASDAQ:EXEL) , Amgen Inc. (NASDAQ:AMGN) - Street Updates
06/09/16 07:15 AMEarnings Report: Exelixis, Inc. (NASDAQ:EXEL), Novavax, Inc. (NASDAQ:NVAX) - Beacon Chronicle
06/08/16 04:07 PMExelixis, Inc. Setting New Standard of Care - Motley Fool
06/08/16 03:03 PMExelixis, Inc. Setting New Standard of Care - Look at what Cabometyx did -- again.
06/08/16 07:20 AMHC Stocks Judgment: Mylan NV (NASDAQ:MYL), Exelixis, Inc. (NASDAQ:EXEL) - share market updates (press release)
06/07/16 09:38 PMExelixis Inc. (EXEL) Hits New 52-week High During June 06 Session - Equities.com
06/07/16 09:38 PMExelixis, Inc. (NASDAQ:EXEL)and Ipsen announced positive data an analysis of trial results of its treatment for ... - Inside Trade
06/07/16 04:02 PMEarnings Trend of the Stocks: Kinder Morgan, Inc. (NYSE:KMI), Exelixis, Inc. (NASDAQ:EXEL) - Beacon Chronicle
06/07/16 02:46 PMExelixis Up on Positive Kidney Cancer Data on Cabometyx -
06/07/16 07:15 AMExelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher -
06/06/16 09:20 PMEXELIXIS INC. (NASDAQ:EXEL) Financial Condition Compared to S&P 500 - CML News
06/06/16 04:52 PMWhy Transocean, Exelixis, and CF Industries Jumped Today - These stocks helped lead the market higher. Find out why.
06/06/16 03:48 PMVascular Biogenics (VBLT), Juno Therapeutics (JUNO), Exelixis (EXEL), and IDI Inc (IDI) Among Top Pre-Market Gainers - TCC
06/06/16 03:48 PMAnalyst's Valuable Buzzers: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) , Exelixis, Inc. (NASDAQ:EXEL) - Street Updates
06/06/16 03:48 PMASCO Updates: Cowen Analysts Weigh In on Exelixis, Inc. (EXEL), Ariad Pharmaceuticals, Inc. (ARIA) and Celldex ... - Smarter Analyst
06/06/16 03:48 PMMonday Morning's Pre-Market Insights: Adamis Pharmaceuticals Corp (ADMP), Exelixis, Inc. (EXEL), Juno ... - Smarter Analyst
06/06/16 03:48 PMExelixis, Inc. Gets Some ASCO Love - Motley Fool
06/06/16 03:18 PMExelixis, Inc. Gets Some ASCO Love -
06/06/16 07:19 AMAnalyst Best Overview on These Stocks: Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), Exelixis, Inc. (NASDAQ ... - Beacon Chronicle
06/06/16 07:19 AMHC Stocks in Top Row: Hologic, Inc. (NASDAQ:HOLX), Exelixis, Inc. (NASDAQ:EXEL) - share market updates (press release)
06/06/16 07:13 AMBRIEF-Exelixis, Ipsen post results from advanced renal cell carcinoma study - * Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX(tm) (cabozantinib) tablets in advanced renal cell carcinoma at 2016...
06/06/16 06:58 AMExelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYXâ„¢ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting - [at noodls] - - Additional data from pivotal METEOR trial underscore clinically meaningful benefit of CABOMETYX across subgroups of patients - SOUTH SAN FRANCISCO, Calif. & PARIS--(BUSINESS WIRE)--Jun. 6, 2016-- Exelixis, ...
06/06/16 01:46 AMBRIEF-Exelixis and Ipsen announce Phase 3 trial results of CABOMETYX - * Announced on Sunday Phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma...
About Exelixis

Exelixis logoExelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: EXEL
  • CUSIP: 30161Q10
Key Metrics:
  • Previous Close: $7.69
  • 50 Day Moving Average: $6.40
  • 200 Day Moving Average: $4.94
  • P/E Ratio: N/A
  • P/E Growth: 0.38
  • Market Cap: $1.76B
  • Current Quarter EPS Consensus Estimate: $-0.83 EPS
Additional Links:
Exelixis (NASDAQ:EXEL) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha